New GPER1 Research Could Revolutionize Psoriasis Treatment Options

New research into the G protein-coupled estrogen receptor 1 (GPER1) has uncovered its potential as a treatment for chronic skin conditions. Scientists found that activating GPER1 slows down the excessive growth of skin cells, a key factor in diseases like psoriasis. The discovery opens doors for more targeted therapies with fewer side effects than current options.

GPER1 works by blocking keratinocyte proliferation, particularly during the G1 phase of the cell cycle. This effect reduces the thick, scaly patches seen in inflammatory skin disorders. Unlike traditional estrogen receptors, GPER1 triggers rapid responses, offering a distinct way to control inflammation.

Studies in animal models showed promising results. When treated with GPER1 agonists, subjects with psoriasis-like inflammation experienced less severe symptoms and fewer pathological changes in the skin. The receptor also disrupts the MAPK/ERK pathway, lowering levels of pro-inflammatory signals like TNF-α and IL-6.

Researchers suggest that developing GPER1-targeted drugs could lead to new topical or systemic treatments. These might provide better safety profiles compared to existing therapies, which often cause widespread side effects. Additionally, measuring GPER1 activity in patients could help tailor treatments, improving outcomes while reducing risks.

As of March 2026, no clinical trials for GPER1-based skin treatments have been registered. Preclinical work continues, but no Phase I-III studies are yet underway. The findings still highlight the growing importance of G protein-coupled receptors (GPCRs) in dermatology, expanding possibilities for future therapies.

The discovery of GPER1's role in skin inflammation offers a clearer path toward more effective treatments. By targeting this receptor, scientists aim to develop therapies that reduce symptoms while minimising side effects. Further research and eventual clinical trials will determine how soon patients could benefit from these advances.